Delayed Deutsche Boerse AG Other stock markets | 5-day change | 1st Jan Change | ||
0.03 EUR | 0.00% | | -7.69% | +93.55% |
Jun. 27 | EARNINGS AND TRADING: Shuka Minerals loss narrows; Atome loss widens | AN |
Jun. 27 | Genflow Biosciences plc Announces Strengthening of Pre-Clinical Efforts | CI |
Financials
Sales 2022 | - | Sales 2023 | - | Capitalization | 4.17M 3.89M |
---|---|---|---|---|---|
Net income 2022 | -1M -934K | Net income 2023 | -1M -934K | EV / Sales 2022 | - |
Net cash position 2022 | 2.36M 2.2M | Net cash position 2023 | 684K 639K | EV / Sales 2023 | - |
P/E ratio 2022 | -5.26x | P/E ratio 2023 | -2.56x | Employees | 5 |
Yield 2022 * | - | Yield 2023 | - | Free-Float | 36.13% |
More Fundamentals * Assessed data
Chart Genflow Biosciences plc
Dynamic Chart
Latest news about Genflow Biosciences plc
EARNINGS AND TRADING: Shuka Minerals loss narrows; Atome loss widens | AN | |
Genflow Biosciences plc Announces Strengthening of Pre-Clinical Efforts | CI | |
EARNINGS AND TRADING: Distil loss widens; Genflow welcomes grant | AN | |
Genflow Biosciences receives 50% of grant for sarcopenia project | AN | |
Genflow Biosciences Secures Grant for Sarcopenia Research Program | MT | |
Home REIT cuts borrowings, Genflow shares restored | AN | |
Genflow Biosciences Resumes London Trading | MT | |
EARNINGS AND TRADING: Solid State and MTI Wireless win deals | AN | |
Genflow Biosciences plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI | |
Genflow Biosciences to Temporarily Halt Trading Amid Delay in FY23 Results Publication | MT | |
Northcoders launches bootcamp; Schroder invests | AN | |
Genflow Biosciences Raises New Funds for Liver Disease Treatment Trials | MT | |
Genflow confirms publication of European patent for SIRT6 | AN | |
Genflow wins new research grants; Seeen margin rises | AN | |
Coro Energy strikes finance deal in Vietnam | AN |
More news
Press releases Genflow Biosciences plc
Genflow Biosciences advances three major programs in fight against ageing diseases | AQ | |
Genflow Biosciences attracts new institutional investors with £715,000 fundraise | AQ | |
Genflow Biosciences Plc to Present Live at the Virtual Life Science Investor Forum March 7th | AQ | |
Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024 | AQ | |
Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024 | GL |
More press releases
Quotes and Performance
1 week | -7.69% | ||
Current month | -10.45% | ||
1 month | -10.45% | ||
3 months | +81.82% | ||
6 months | +93.55% | ||
Current year | +93.55% |
More quotes
Highs and lows
1 week
0.02
0.03
1 month
0.02
0.04
Current year
0.01
0.04
1 year
0.01
0.04
3 years
0.01
0.16
5 years
0.01
0.16
10 years
0.01
0.16
More quotes
Managers and Directors - Genflow Biosciences plc
Managers | Title | Age | Since |
---|---|---|---|
Eric Jean Marie Leire FOU | Founder | 66 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Guy-Charles Fanneau de la Horie BRD | Director/Board Member | 64 | 22-06-28 |
Tamara Joseph CHM | Chairman | 61 | 22-06-28 |
Eric Jean Marie Leire FOU | Founder | 66 | 19-12-31 |
More insiders
Quotes
Date | Price | Change |
---|---|---|
24-06-28 | 0.03 | 0.00% |
24-06-27 | 0.03 | +3.45% |
24-06-26 | 0.029 | -3.33% |
24-06-25 | 0.03 | 0.00% |
24-06-24 | 0.03 | -7.69% |
Delayed Quote Deutsche Boerse AG, June 28, 2024 at 03:15 am EDT
More quotes
Company Profile
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
Sector
Calendar
2024-09-26 - Q2 2024 Earnings Release (Projected)
More about the company
Income Statement Evolution
More financial data
Sector Bio Therapeutic Drugs
1st Jan change | Capi. | |
---|---|---|
VERTEX PHARMACEUTICALS INCORPORATED | +16.13% | 122B |
REGENERON PHARMACEUTICALS, INC. | +19.65% | 113B |
ARGENX SE | +20.67% | 26.49B |
BIONTECH SE | -23.84% | 19.4B |
GENMAB A/S | -17.73% | 16.24B |
WUXI APPTEC CO., LTD. | -45.95% | 15.15B |
BEIGENE, LTD. | -19.28% | 15.4B |
SAREPTA THERAPEUTICS, INC. | +63.81% | 14.93B |
NEUROCRINE BIOSCIENCES, INC. | +1.94% | 13.52B |
Bio Therapeutic Drugs
- Stock Market
- Equities
- GENF Stock
- WQ5 Stock